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Scientific activity (2006-09) 
Papers (ISI)  189 (79 1st Q) 
Books and chapters   40  
Invited conferences        58 
Research projects   33 
Clinical trials    32 





2006 2007 2008 2009
Papers
Papers 1Q
    
1) Clinical and molecular epidemiology of relevant bacteria  
     in community and in health-care associated infections 
2) Clinical and experimental studies on bacterial meningitis 
3) Clinical and experimental studies on prosthetic infections 
            4) Optimizing process of care in community-acquired pneumonia 
5) Tuberculosis: Pathogenesis; Rapid detection of resistance; 
                  Prevention of infection in immunossupressed patients 
6) HIV infection and AIDS: Secular trends in clinical outcomes; 
    Antirretroviral therapy; Cardiovascular risk assessment.  
7) Infections in cancer and transplant patients: Emerging 
    pathogens; Prevention and therapy of viral and fungal infections 
Main Research Lines 
Relevance of CAP 
  5 - 10 cases por 1000 persons/year 
  25 - 40 cases among > 70 years old 
  30% patients hospitalized  
  Persistant  morbidity and mortality  
  Substantial economic costs 
  New populations at risk 
  Emerging pathogens 
  Antimcrobial resistance 
CAP in Bellvitge Hospital:  Background 
The early studies 
 Neumonía neumocócica bacteriémica: a propósito de 70 casos. 
   Gudiol F et al.  Medicina Clínica, 1977 
 Neumonía aguda de adquisición extrahospitalaria. Distribución  
   etiológica de 451 casos.  
   Solans P et al. Revista Clínica Española, 1978 
The penicillin-resistance days 
 Risk factors and response to penicillin therapy in adults with 
  bacteremic pneumonia caused by penicillin-resistant pneumococci 
  Pallares R et al. New England Journal of Medicine,1987 
 Clindamycin vs Penicillin for anaerobic lung infections: High rate 
   of failures associated with penicillin-resistant B. melaninogenicus 
   Gudiol F et al. Archives of Internal Medicine, 1990  










1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Early mortality in CAP 
P<0.001 
1995: 4%                2005: 1.4% 
 Initiated 1995 (Fis 95/1100) 
 Adult non-immunossupressed pts hospitalized with CAP 
 Clinical pathway 
 CAP database, 4200 episodes 
 Prospective cohort studies 
 Randomized trials 
 Collaborations 
   Microbiology: R. Verdaguer, F. Tubau, J. Liñares 
   Respiratory: J.Dorca, F. Manresa 
   Infectious diseases: J. Carratalà, F. Gudiol 
   Fellows: A. Fernández, S. Fernández, C. García-Vidal 
                 A. Mykietiuk, B. Rosón, N.Sabé, D. Viasús 
Optimizing process of care in CAP 
Diagnosis   
Risk assessment 





   Early outcomes 
Length of stay 
   
Long-term follow-up  
Special populations   
Targeted clinical studies on CAP 
Clin Infect Dis    2000 
Clin Infect Dis    2003 
Clin Infect Dis    2004 
Clin Infect Dis    2001 
Ann Intern Med    2005 
Microb Drug Res    2001 
Clin Infect Dis    2005 
Eur J Clin Microb   2010 
Arch Intern Med   2004 
Eur Resp J    2008 
Thorax      2010 
Eur J Clin Microb  2006 
Clin Microb Infect 2009 
Medicine (Balt)    2003 
Arch Intern Med   2007 
Medicine (Balt)    2010 
Medicine (Balt)    2010 
 
Age  > 50 years 
Coexisting conditions  
Abnormalities on 
 physical examination 
Assign patient to 










Men (age in years) 
Women  (age    –  10) 
   Nursing Home + 10 
Coexisting illnesses 
Cancer  + 30 
Liver disease +20 
Congestive heart failure +10 
Cerebrovascular disease +10 
Renal disease  +10 
Findings on physical examination 
Altered mental status 
  
+20 
Respiratory rate   30  min +20 
Systolic BP < 90 mmHg +20 
Temp.  40ºC or <35ºC +15 
Pulse   125 min  +10 
Laboratory and radiographic findings 
pH<7.35 +30 
Urea>11 mmol/L  +20 
Hematocrit  <30% +10 
Na <130 mmol/L +20 
Glucose >14  mmol/L +10 
PaO2<60 mmHg +10 
Pleural effusion  +10 
Fine MJ. N Engl J Med 1997 
THE PNEUMONIA SEVERITY INDEX (PSI) 
Risk Classes (PSI) and Mortality  
   Classes        Points             Mortality           Site of Care 
                                             (30 days)  
       I          -               0,1 %          Ambulatory 
      II         70               0,6 %               Ambulatory 
      III     71 - 90          1,9 %                    ?? 
      IV      91 – 130          9,3 %                Hospital 
      V         >  130            27,0 %               Hospital     
 230 




 I - III 
HIGH RISK 
CLASES 










Risk classes, reasons for hospitalization  
and outcomes in 533 patients with CAP 
  
Randomized study 
Outpatient care compared with hospitalization 
in low-risk patients with CAP: 
A randomized trial 
Patients:  Pts in PSI class II-III without extenuating conditions 
Intervention: Pts were randomly assigned to outpatient care 
                       or hospitalization, and received oral or switch 
                       therapy with levofloxacin, respectively 
Primary end point:  Overall successful outcome, according to 
                                  strict predefined criteria 
Secondary end points:  Quality of life, satisfaction with care   
RISK CLASSES II - III  
n = 427 
RANDOMIZED  





 n = 101 n = 102 
EXCLUDED (n= 8) 
 ITT 
 PP 
EXCLUDED (n= 13) 
STUDY PROFILE 
 
EXCLUDED (n= 203) 
 
114   Respiratory failuere 
  14   Prior quinolones 
  10   Unstable comorbidities 
    9   Empyema 
    8   Social problems 
    2   Quinolone alergy 
    1   Inhability to oral intake  
  45   Refused to parcicipate 
Outcomes: Intention to Treat Analysis 
                                Home (114)   Hospital (110) 
                                   (%)               (%) 
                                                                        
Overal Successful Outcome             83.6              80.7  
Drug Adverse Effects                    9.1                9.6  
Medical Complications                          0.9                2.6  
Aditional Visits                                       1.8                1.7 
Antibiotic Therapy Changes                  2.7                3.5  
Readmissions (30 days)                        6.3                7.0 
























Hospitalization day 7 Outpatient care day 30
General Population
Outpatient care day 0 Outpatient care day 7
No differences between groups 
                              Satisfaction with Care 
   Outpatient      Hospital       Dif.         IC  95%    p 
      91.2%            79.1%        12.1       1.8 – 22.5       0.03 
Quality of Life (SF-36) and Satisfaction with Care 
Effectiveness of a 3-Step Clinical Pathway to Reduce 
Duration of Intravenous Antibiotic Therapy and 
Length of Stay in Community-Acquired Pneumonia  
Design: Randomized, controlled trial (ISRCTN17875607) 
Setting: 2 tertiary care hospitals in Barcelona. 
Patients: Immunocompetent adults with CAP requiring hosp. 
Exclusion criteria: Lack of consent, ICU admission, shock, 
      aspiration pneumonia, empyema, inability to oral intake. 
Primary end point: Length of stay 
Secondary end points: Duration of iv antibiotic therapy, 
      adverse effects, readmissions, overall mortality (30 d) 
3-STEP CLINICAL PATHWAY 
1st -   EARLY MOBILIZATION 
2nd -  EARLY SWITCH TO ORAL ANTIBIOTIC THERAPY 
3rd -  HOSPITAL DISCHARGE 
 Sitting out of bed or ambulating for at least 20 min during 
    the first 24 h of hospitalization 
  Progressive mobilization during hospitalization 
 Temperature 37,8ºC, improvement or resolution of symptomps, 
   ability to mantain oral intake, hemodynamic stability,  
   stable comorbid conditions 
 Abscence of instability criteria: temperature >37,8ºC;  RR > 24’; 
  HR > 100’;  SBP  90 mm Hg; oxygen saturation <90%; altered  
  mental status; inability to mantain oral intake 
ASSESSED FOR ELIGIBILITY  (n = 620) 
RANDOMLY ASSIGNED (n = 401) 
INTERVENTION 
(n = 200) 
 CONTROL  
(n = 201) 










OUTCOMES OF STUDY PATIENTS BY TREATMENT GROUP 
Intention to Treat Analysis 
                                Intervention     Control 
                                         (n=200)             (n=201) 
 
LOS, median days        3.9 (3.7-4.2)   6.2 (5.6-6.9)   <.0001 
Time to switch, days     2.0 (1.7-2.2)   4.0 (3.4-4.6)   <.0001 
Adverse drug reactions      4.5%              16.0%        <.0001 
        Phlebitis                      4.0%              10.5% 
Readmission (< 30d)          9.0%               7.5%           .59 
Overall mortality (< 30d)     2.0%               1.0%           .45 
 
Summary 
Through prospective studies focused on crucial  
clinical problems of CAP, we have  
 Refined our knowledge on this condition 
 Improved the patients process of care 
 Disseminated scientific evidence for 
   its proper management 
 Provided medical education to our fellows 
